Advanced cancers destined to recur after treatment with single drugs that 'target' tumor cells: study

June 13, 2012 in Cancer

Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.

In a study of 28 advanced patients treated with the monoclonal antibody panitumumab, the Johns Hopkins Kimmel Cancer Center team reports that drug-resistance tumor cell mutations appear in the blood of patients five to seven months later, and that low levels of these mutations exist in nearly all tumors before the therapy begins, making the cancers predestined to recur.

"These resistance mutations develop by chance as cancer cells divide so that tumors always contain thousands of resistance cells," says Luis Diaz, M.D., associate professor of oncology and director of the Swim Across America laboratory at Johns Hopkins, who says the findings likely apply to any targeted cancer therapy.

"The best chance for a cure is when a tumor is very small, but when the cancer is advanced, our research quantifies the probability that we can achieve cures with single-agent targeted therapies," says Bert Vogelstein, M.D., professor and co-director of the Ludwig Center at Johns Hopkins and, Howard Hughes Medical Institute investigator. "Long-term remissions of advanced cancers will be nearly impossible with single targeted agents," he adds.

The Johns Hopkins scientists analyzed blood samples taken from 28 patients with advanced . These patients were enrolled in a clinical trial of panitumumab, one of a new and growing class of , or that homes in on cancer cells' vital growth pathways. In the case of panitumumab, the agent targets a growth-factor receptor called EGFR. Patients most likely to respond to the drug also have normal copies of the KRAS gene in their tumors.

Twenty-four of the 28 patients in the study had normal KRAS gene copies in their tumors, and four had mutations in KRAS, serving as a control group. Blood samples were taken before beginning the therapy and at four-week intervals during the therapy, for a total of 169 combined blood draws.

Virtually all cancers shed DNA material into the blood, according to the researchers, and provide an easy route to collecting molecular evidence from lesions typically inaccessible for surgical biopsy. "The amount of tumor DNA found in the blood is akin to tests used to determine HIV viral load," says Diaz.

In their analysis, reported online June 13 in the journal Nature, the scientists found that nine of the 24 patients with normal KRAS genes (38 percent) exhibited KRAS mutations detectable in the blood within five to seven months of beginning therapy. KRAS mutations were detected in three patients before imaging scans showed metastatic tumor growth. Then, working with Martin Nowak, Ph.D., and his team from Harvard University, the investigators used mathematical models to calculate when KRAS mutations likely originated. Nowak and colleagues determined that KRAS mutations were present prior to the initiation of treatment with panitumumab.

"The probability that the were absent at the beginning of treatment is exceedingly low," says Vogelstein, leading the team to conclude that the development of drug-resistance is a fait accompli. The time it takes for cancers to recur is determined simply by how long it takes with mutant genes to multiply, he adds.

The research team says that combination therapies are the best chance for longer remissions. "The good news is that there is a limited number of pathways that go awry in cancer, so it should be possible to develop a small number of agents that can be used in a large number of ," says Vogelstein. "However, I hope this research will help stimulate the testing of new drugs as combination therapies much earlier in the drug approval process than the current norm."

More information: DOI: 10.1038/nature11156 , DOI: 10.1038/nature11219

Journal reference: Nature search and more info website

Provided by Johns Hopkins University School of Medicine search and more info website

4 /5 (1 vote)  

Rank 4 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

Low radiation scans help identify cancer in earliest stages

A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...

Cancer created 1 hour ago | popularity not rated yet | comments 0

Poliovirus vaccine trial shows early promise for recurrent glioblastoma

An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

Cancer created 2 hours ago | popularity not rated yet | comments 0

Racial disparities in the surgical management of non-small cell lung cancer

The surgical management of non-small cell lung cancer (NSCLC) in U.S. hospitals varies widely depending on the race of the patient, according to a new study.

Cancer created 6 hours ago | popularity not rated yet | comments 0

Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency

Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients ...

Cancer created 7 hours ago | popularity not rated yet | comments 0

New tumour-killer shows great promise in suppressing cancers

Scientists from Nanyang Technological University (NTU) and Lund University, Sweden, have bioengineered a novel molecule which has been proven to successfully kill tumour cells.

Cancer created 7 hours ago | popularity 5 / 5 (1) | comments 0


Antidepressant reduces stress-induced heart condition

A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.

Americans still making unhealthy choices, CDC reports

(HealthDay)—The overall health of Americans isn't improving much, with about six in 10 people either overweight or obese and large numbers engaging in unhealthy behaviors like smoking, heavy drinking or ...

CDC presents recent trends in health behaviors of US adults

(HealthDay)—In 2008 to 2010, the prevalence of key health behaviors among U.S. adults varied, with about one in five adults current smokers and 62.1 percent overweight or obese, according to a report presented ...

Study examines outbreak of spinal infections in Michigan

(HealthDay)—Factors such as increased case finding may explain why Michigan had half of the total spinal infections associated with contaminated methylprednisolone acetate in the recent fungal meningitis ...

Early use of tracheostomy for mechanically ventilated patients not associated with improved survival

For critically ill patients receiving mechanical ventilation, early tracheostomy (within the first 4 days after admission) was not associated with an improvement in the risk of death within 30 days compared to patients who ...

CDC says high number of public pools contain microbes

(HealthDay)—Three-quarters of public schools in the metro Atlanta area contain microbes, including bacteria indicating the presence of fecal matter, according to research published in the May 17 issue of ...